Purpose: To evaluate the risk of postimplantation syndrome associated with endovascular aneurysm sealing (EVAS) and endovascular aneurysm repair (EVAR) in patients treated for abdominal aortic aneurysm (AAA). Methods: From December 2013 to May 2015, 41 AAA patients treated with EVAS (mean age 72±9 years; 38 men) and 63 with EVAR (mean age 74±10 years; 55 men) at a single center were retrospectively reviewed. To control for treatment selection bias, propensity score matching was used to compare outcomes by treatment mode. Main outcomes were postimplantation syndrome (defined as temperature >38°C and leukocyte count >12,000/µL), inflammatory response markers [platelets and high-sensitivity C-reactive protein (hs-CRP)], and clinical complications through 30 days. Results: In 39 matched patients per group, the incidences of postimplantation syndrome (p=0.07), mean body temperature (p=0.05), mean leukocyte count (p=0.003), and mean hs-CRP (p<0.001) were proportionally lower with EVAS vs EVAR. Serious adverse events (0% vs 12.8%, p=0.05) and endoleaks (0% vs 10.3%, p=0.13) through 30 days were less frequent with EVAS, but the group differences were not significantly different. The choice of endovascular graft material influenced postoperative and 30-day clinical outcomes, with greater overall risk observed with polyester stent-grafts. Conclusion: Endovascular aneurysm sealing is associated with a blunted systematic inflammatory response compared with EVAR. Polyester stent-grafts induce the greatest periprocedural inflammatory response.
Introduction
Inflammation is thought to play an important role in the development and pathogenesis of abdominal aortic aneurysm (AAA). 1 AAA disease is characterized by destruction of elastin and collagen in the media and adventitia, loss of medial smooth muscle cells with thinning of the vessel wall, and transmural infiltration of lymphocytes and macrophages. 2, 3 While the initiating factors of the inflammatory cascade are not completely understood, once the process has begun, it appears to be self-perpetuating, with progressive aortic degeneration and aneurysm expansion. 4 An important mediator of the inflammatory cascade is intraluminal thrombus, which may trigger a systemic inflammatory response and influence postoperative outcomes following endovascular aneurysm repair (EVAR). 5 The systemic inflammatory response immediately following EVAR, known as the postimplantation syndrome (PIS), is characterized by an increase in body temperature, leukocytosis, and sometimes coagulation disturbances. The incidence of PIS ranges from 14% to 60%, [6] [7] [8] [9] [10] [11] with extended procedure time and polyester graft material associated with higher PIS risk. However, the intrinsic pathways underlying PIS remain undefined. Although PIS is generally thought to be well-tolerated in most patients, the syndrome is not completely benign and is associated with greater postoperative morbidity, prolonged hospitalization, and greater risk of readmission. 7 Endovascular aneurysm sealing (EVAS) is a newer technology that completely seals the aneurysm sac from the systemic circulation via polymer-filled endobags surrounding the endograft flow lumens. Given this novel mechanism of action, EVAS may prevent biochemical inflammatory mediators originating from intrasac thrombus from exerting systemic effects. This study addressed the hypothesis that EVAS may blunt the systemic inflammatory response often seen in EVAR patients, reducing the risk of PIS.
Methods

Study Design
A retrospective review was conducted of AAA patients who were electively treated with EVAS between December 2013 and December 2015 or EVAR between January 2011 and May 2015 at a single center. Patients were excluded from the analysis owing to suspected infection, ruptured AAA, prior EVAR, need for concomitant open surgical procedures (eg, vascular reconstruction), or use of nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, or corticosteroids. The institutional review board approved the study and waived the need for patient consent.
Patients underwent preoperative computed tomography (CT) scans to determine aortoiliac morphology and suitability for endovascular treatment. Aneurysm diameter and flow lumen volume were measured using automatic 3-dimensional sizing software (EndoSize; Therenva SAS, Rennes, France). Aneurysm volume was measured with open-source software (OsiriX MD; Pixmeo Labs, Geneva, Switzerland). Thrombus volume was calculated as the difference in AAA volume and flow lumen volume. All volumetric measurements were taken from the lowest renal artery to the iliac bifurcation on both sides.
The decision to use EVAS or EVAR was based on physician preference. Endovascular procedures were conducted under general anesthesia and followed a standard vascular protocol, including intravenous administration of heparin (100 U/kg). The procedures were performed by the senior author (P.B.) or 2 other surgeons under his direct supervision. Samples (15 mL) of peripheral venous blood were obtained once a day in the 72 hours after EVAS or EVAR.
Patient Cohort
During the study period, 210 patients underwent an endovascular procedure for AAA. Main reasons for exclusion were a complex hybrid procedure (n=46), fenestrated or branched procedure (n=26), chimney procedure (n=15), AAA rupture (n=14), prior EVAR repair (n=3), and associated thoracic endovascular aortic repair (n=2). Of the 104 patients remaining, 41 were treated with EVAS (mean age 72±9 years; 38 men) and 63 with EVAR (mean age 74±10 years; 55 men). Baseline patient characteristics are presented in Table 1 . All EVAS patients were treated with the Nellix system (Endologix, Inc, Irvine, CA, USA). The most commonly used stent-grafts in the EVAR group were Anaconda (Vascutek, Renfrewshire, Scotland), Excluder (W.L. Gore & Associates, Flagstaff, AZ, USA), and Endurant/2 (Medtronic, Santa Rosa, CA, USA).
Outcome Measures
Main outcomes of interest were body temperature, white blood cell (WBC) count, platelet count, and high-sensitivity C-reactive protein (hs-CRP) concentration. The maximum value for each outcome during the 72-hour postoperative period was used for analysis. PIS was defined as temperature >38°C and WBC count >12,000/µL. Patients were discharged in the absence of complications and with body temperature and WBC count less than the above thresholds. Clinical outcomes included serious adverse events (SAEs), 12 endoleak, and mortality through 30-day follow-up. Endoleak was assessed by the implanting surgeon using postoperative CT and contrast-enhanced ultrasound.
Statistical Analysis
A 1:1 matched propensity score analysis was used to adjust for treatment selection bias and possible imbalances in baseline patient characteristics between groups. Covariates included in the propensity matching model were age, sex, body mass index, American Society of Anesthesiologists classification, smoking history, coronary heart disease, chronic obstructive pulmonary disease, diabetes, AAA diameter, AAA volume, sac thrombus volume, sac thrombus percentage, and iliac artery diameter. Logistic regression was used to estimate the propensity score, which is the probability that a patient received EVAS. A nearest neighbor greedy match technique without replacement was used, with a caliper size of 0.2 standard deviations of the logit of the propensity score. 13 This matched each EVAS patient to an EVAR patient with the closest propensity score provided the scores differed by no more than the caliper.
Baseline characteristics were reported in all patients and in the propensity score-matched patients; 30-day data were reported in the matched subsets only. Continuous variables were reported as mean ± standard deviation or median (interquartile range). Categorical variables were presented as counts (percentages). Between-group differences in propensity matched patients were tested using the paired t test for normal continuous data, the Wilcoxon test for nonparametric continuous data, or the McNemar test for categorical data. Subgroup analysis of outcomes by stent-graft composition was performed using the independent-samples t test, Mann-Whitney U test, or Fisher exact test. The threshold of statistical significance was p<0.05. Statistical analyses were performed using Predictive Analytics Software (version 22; IBM, Inc, Armonk, NY, USA) with the propensity score matching (PSM) extension bundle.
Results
Baseline demographics, risk factors, and aortoiliac anatomy were comparable between groups in all patients and the matched subsets (n=39 per group; Table 1 ). Procedure time and hospital stay ( Table 2) were also comparable between groups. The incidence of PIS was 5.1% (2/39; 95% CI 0.6% to 17.3%) in the EVAS cohort and 20.5% (8/39; 95% CI 9.3% to 36.5%) with EVAR (p=0.07). Each component of the PIS definition was less frequent in the EVAS group, with lower temperature (p=0.05), WBC count (p=0.003), and hs-CRP (p<0.001) relative to EVAR; there was no difference in platelet count (p=0.48).
In the propensity score-matched subsets, SAEs [0% vs 12.8% (5/39), p=0.05] and endoleaks [0% vs 10.3% (4/39), p=0.13] through 30 days were less frequent with EVAS, but the proportions were not significantly different. The SAEs reported in the EVAR group included cardiac decompensation (n=2), secondary intervention for type I endoleaks (n=2), and angina pectoris with elevated troponin levels (n=1). All SAEs required intensive care unit stay. In addition to the 2 type I endoleaks in the EVAR group, there were also 2 untreated type II endoleaks.
The choice of endovascular graft material influenced postoperative and 30-day clinical outcomes (Table 3) . Compared with the 5.1% rate of PIS in the EVAS patients, no patient treated with PTFE stent-grafts developed the Figure 1 ). Patients treated with polyester stent-grafts experienced higher temperature (p=0.02), WBC count (p<0.001), and hs-CRP levels (p<0.001) relative to EVAS and PTFE stent-grafts. SAEs were more frequent in patients treated with polyester stent-grafts. Endoleak incidence was 0% with EVAS, 15% (2/13) with PTFE stent-grafts (1 type I and 1 type II), and 8% (2/26) with polyester stent-grafts (1 type I and 1 type II; p=0.04).
There was no clear association of PIS with clinical outcomes. Hospital stay was comparable in patients with vs without PIS (10 vs 9 days, p=0.65). The incidences of SAE (20% vs 4%, p=0.12) and endoleak (20% vs 3%, p=0.08) were proportionally higher in patients with PIS but did not achieve statistical significance.
Discussion
This study demonstrated that EVAS is associated with a blunted systematic inflammatory response compared to EVAR. Further, polyester stent-grafts induced the greatest postoperative inflammatory response relative to EVAS and PTFE stent-grafts. Although SAEs and endoleaks were observed less frequently with EVAS, the outcomes were not statistically different. Overall, these results suggest that graft composition and complete AAA sac thrombus sealing influence the systemic inflammatory response following endovascular AAA treatment.
The incidence of PIS in the current study was 5% with EVAS and 21% with EVAR. In comparison, previous EVAR studies report PIS in 14% to 60% of patients. [6] [7] [8] [9] [10] [11] In most cases, PIS is generally well-tolerated, but in some patients, it may lead to severe complications, including cardiovascular events, renal function impairment, and multisystem organ failure during the postoperative period. 14 In the current study, 30-day SAE rates were higher in patients with vs without PIS (20% vs 4%), although these rates were not significantly different. While no cause and effect relationship can be determined in this study due to a limited sample size, these preliminary results suggest a possible relationship between systemic inflammation and complication risk in the perioperative period following endovascular AAA treatment.
The potential role of endoleak in the inflammatory process is worthy of future study. The presence of type II endoleak may provide a sustained pathway for signaling proteins to reach the systemic circulation. 15 Successful exclusion of intraluminal thrombus with EVAR does not necessarily confer protection from the proinflammatory response, and several groups have demonstrated prothrombotic and inflammatory interactions persisting after EVAR. 16 Davies and colleagues 15 concluded that partial sac thrombosis occurs in the presence of a type II endoleak, and the aneurysm thrombus forms a sump of proinflammatory mediators, which remain in contact with the systemic circulation. Shalaby and colleagues 17 reported that patients with systemic inflammatory disease developed more endoleaks despite comparable baseline characteristics, had greater sac expansion, and required more secondary interventions. In the current study, endoleak rates were higher in patients with PIS (20% vs 7% without), although these rates were not significantly different. The positive results with EVAS in this study may be partially attributable to complete aneurysm sac sealing, which lowers endoleak risk and effectively limits proinflammatory mediators from entering the systemic circulation.
Limitations
The independent interrelationships among endovascular treatment type, inflammatory response intensity, and 30-day SAEs in this study are difficult to assess given the retrospective evaluation, limited sample size, and consequent risk of confounding and bias. Despite the use of propensity score matching to adjust for treatment selection bias, unmeasured patient characteristics may have influenced outcomes. An additional limitation of this study was that hs-CRP, WBC count, and platelets were not routinely collected preoperatively, and thus, the change in these biochemical indices could not be quantified. Physician experience with EVAS was more limited, and there was little overlap in treatment periods between groups. Outcomes varied due to different implanting surgeons and stent-graft manufacturers. Given these limitations, the current findings should be viewed as hypothesis generating. A prospective multicenter study comparing the inflammatory response of EVAS vs EVAR is warranted.
Conclusion
Endovascular aneurysm sealing is associated with a blunted systematic inflammatory response compared to EVAR. Polyester stent-grafts induce the greatest postoperative inflammatory response.
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